AbbVie Inc (ABBV.N)
15 Jun 2018
Get access to over 18 million research reports from over 1,700 sources.
For several years, Reuters.com has provided analyst research reports for downloading. In an effort to streamline our website, analyst research will now be available from our dedicated page for Thomson Reuters On Demand, and the Reuters service will discontinue as of September 30, 2016.
Thomson Reuters On Demand provides over 18 million research reports from 1,700 sources.
Moreover, Thomson Reuters On Demand offers fast and cost-effective solutions that would allow you to retrieve information on:
- private equity
- third-party document and information retrieval
- and much, much more…
Click here to request a report and the team of expert analysts will get back to you shortly, to ensure you get the report you need.
|63||2013||Chairman of the Board, Chief Executive Officer|
|49||2013||Executive Vice President, Chief Financial Officer|
|51||2014||Executive Vice President - Research & Development, Chief Scientific Officer|
|54||2013||Executive Vice President, External Affairs, General Counsel and Corporate Secretary|
|54||2013||Executive Vice President - Commercial Operations|
- BRIEF-FDA Approves Abbvie & Genentech USA's VENCLEXTA For Treating Two Types Of Blood Cancers
- U.S. drug prices hit by insurer tactic against copay assistance -analysis
- UPDATE 1-AbbVie's rheumatoid arthritis drug succeeds in late-stage study
- AbbVie's rheumatoid arthritis drug succeeds in late-stage study
- RPT-U.S. FDA wants to shorten new drug monopolies to cut costs